Your browser doesn't support javascript.
loading
A case control investigation of COVID-19 associated mucormycosis in India.
Anand, Tanu; Mukherjee, Aparna; Satija, Aanchal; Velamuri, Poonam Sharma; Singh, Kh Jitenkumar; Das, Madhuchhanda; Josten, Kripa; Yadav, Pragya D; Sahay, Rima R; Keche, Archana Y; Nagarkar, Nitin M; Gupta, Prashant; Himanshu, D; Mistry, Sejal N; Patel, Jimy D; Rao, Prajwal; Rohatgi, Shalesh; Ghosh, Soumitra; Hazra, Avijit; Kindo, Anupma Jyoti; Annamalai, Radha; Rudramurthy, Shivaprakash M; Singh, Mini P; Shameem, Mohammad; Fatima, Nazish; Khambholja, Janakkumar R; Parikh, Sangita; Madkaikar, Manisha; Pradhan, Vandana D; Kataria, Sushila; Sharma, Pooja; Panda, Samiran.
Afiliação
  • Anand T; Indian Council of Medical Research, New Delhi, India.
  • Mukherjee A; Indian Council of Medical Research, New Delhi, India.
  • Satija A; Indian Council of Medical Research, New Delhi, India.
  • Velamuri PS; Indian Council of Medical Research, New Delhi, India.
  • Singh KJ; ICMR-National Institute of Medical Statistics, New Delhi, India.
  • Das M; Indian Council of Medical Research, New Delhi, India.
  • Josten K; Indian Council of Medical Research, New Delhi, India.
  • Yadav PD; ICMR-National Institute of Virology, Pune, India.
  • Sahay RR; ICMR-National Institute of Virology, Pune, India.
  • Keche AY; All India Institute of Medical Sciences, Raipur, India.
  • Nagarkar NM; All India Institute of Medical Sciences, Raipur, India.
  • Gupta P; King George's Medical University, Lucknow, India.
  • Himanshu D; King George's Medical University, Lucknow, India.
  • Mistry SN; Pandit Dindayal Upadhyay Medical College, Rajkot, India.
  • Patel JD; Pandit Dindayal Upadhyay Medical College, Rajkot, India.
  • Rao P; Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pune, India.
  • Rohatgi S; Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pune, India.
  • Ghosh S; Institute of Post Graduate Medical Education and Research, Kolkata, India.
  • Hazra A; Institute of Post Graduate Medical Education and Research, Kolkata, India.
  • Kindo AJ; Sri Ramachandra Medical College and Research Institute, Chennai, India.
  • Annamalai R; Sri Ramachandra Medical College and Research Institute, Chennai, India.
  • Rudramurthy SM; Post Graduate Institute of Medical Education and Research, Chandigarh, India.
  • Singh MP; Post Graduate Institute of Medical Education and Research, Chandigarh, India.
  • Shameem M; Jawaharlal Nehru Medical College Aligarh Muslim University, Aligarh, India.
  • Fatima N; Jawaharlal Nehru Medical College Aligarh Muslim University, Aligarh, India.
  • Khambholja JR; Smt. NHL Municipal Medical College, Ahmedabad, India.
  • Parikh S; AMC MET Medical College, Ahmedabad, India.
  • Madkaikar M; ICMR-NIIH, Mumbai, India.
  • Pradhan VD; ICMR-NIIH, Mumbai, India.
  • Kataria S; Medanta-The Medicity, Gurugram, India.
  • Sharma P; Medanta-The Medicity, Gurugram, India.
  • Panda S; Indian Council of Medical Research, New Delhi, India. pandasamiran@gmail.com.
BMC Infect Dis ; 22(1): 856, 2022 Nov 16.
Article em En | MEDLINE | ID: mdl-36384482
ABSTRACT

BACKGROUND:

Increased occurrence of mucormycosis during the second wave of COVID-19 pandemic in early 2021 in India prompted us to undertake a multi-site case-control investigation. The objectives were to examine the monthly trend of COVID-19 Associated Mucormycosis (CAM) cases among in-patients and to identify factors associated with development of CAM.

METHODS:

Eleven study sites were involved across India; archived records since 1st January 2021 till 30th September 2021 were used for trend analysis. The cases and controls were enrolled during 15th June 2021 to 30th September 2021. Data were collected using a semi-structured questionnaire. Among 1211 enrolled participants, 336 were CAM cases and 875 were COVID-19 positive non-mucormycosis controls.

RESULTS:

CAM-case admissions reached their peak in May 2021 like a satellite epidemic after a month of in-patient admission peak recorded due to COVID-19. The odds of developing CAM increased with the history of working in a dusty environment (adjusted odds ratio; aOR 3.24, 95% CI 1.34, 7.82), diabetes mellitus (aOR 31.83, 95% CI 13.96, 72.63), longer duration of hospital stay (aOR 1.06, 95% CI 1.02, 1.11) and use of methylprednisolone (aOR 2.71, 95% CI 1.37, 5.37) following adjustment for age, gender, occupation, education, type of houses used for living, requirement of ventilatory support and route of steroid administration. Higher proportion of CAM cases required supplemental oxygen compared to the controls; use of non-rebreather mask (NRBM) was associated as a protective factor against mucormycosis compared to face masks (aOR 0.18, 95% CI 0.08, 0.41). Genomic sequencing of archived respiratory samples revealed similar occurrences of Delta and Delta derivates of SARS-CoV-2 infection in both cases and controls.

CONCLUSIONS:

Appropriate management of hyperglycemia, judicious use of steroids and use of NRBM during oxygen supplementation among COVID-19 patients have the potential to reduce the risk of occurrence of mucormycosis. Avoiding exposure to dusty environment would add to such prevention efforts.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limite: Humans País/Região como assunto: Asia Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limite: Humans País/Região como assunto: Asia Idioma: En Ano de publicação: 2022 Tipo de documento: Article